自体造血干细胞移植治疗系统性硬化症的长期有效性与安全性:NISSC1-LTE队列研究
2年、5年和10年无进展生存率分别为81%、72%和60%,43%患者10年内维持无免疫抑制治疗的缓解。研究为自体HSCT的长期疗效和晚期并发症提供了真实世界数据。
要点
- 自体HSCT后10年无进展生存率为60%,43%患者长期维持无免疫抑制治疗缓解。
- 移植相关死亡占6%,疾病进展死亡占11%,晚期恶性肿瘤和严重感染各占3%。
- 长期随访数据可作为新兴细胞治疗方案的疗效比较基准。
核心结论
- 自体HSCT在重症进展型系统性硬化症中显示持续长期获益,10年无进展生存率达60%,近半数患者可脱离免疫抑制治疗维持缓解。
研究设计与样本
- NISSC1-LTE为队列研究,随访80例于2012年12月4日至2016年1月19日期间接受首次自体HSCT的重症进展型系统性硬化症患者,来自法国、德国、荷兰、意大利、西班牙、瑞士和巴西的13个中心。
- 主要终点为无进展生存,定义为从基线存活且无系统性硬化症进展证据;同时分析晚期并发症包括恶性肿瘤、继发性自身免疫病、感染和主要不良心血管事件。
主要发现
- 无进展生存率2年为81%(95%CI 71-88),5年为72%(95%CI 61-81),10年为60%(95%CI 47-71)。
- 研究期间18例患者死亡,死因包括自体HSCT相关5例(6%)、疾病进展9例(11%)、移植后恶性肿瘤2例(3%)和晚期严重感染2例(3%)。
- 34例(43%)患者在10年内维持无免疫抑制治疗的缓解。
临床怎么用
- 对于早期重症进展型系统性硬化症患者,自体HSCT是可考虑的治疗选择,长期随访显示持续无进展生存和脱离免疫抑制治疗的可能。
- 移植后需长期监测疾病进展、恶性肿瘤、继发性自身免疫病、感染和心血管事件等晚期并发症。
局限性
- 12例患者失访,其中5例随访不足5年。
- 研究为观察性队列,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic sclerosis is a rare and heterogeneous chronic autoimmune disease. It has the highest mortality of the rheumatic diseases and few treatment options exist. Autologous haematopoietic stem-cell transplantation (HSCT) is an effective and established therapeutic option in selected patients with early severe systemic sclerosis. This study aimed to evaluate the long-term safety and effectiveness of autologous HSCT in patients with systemic sclerosis in real-life clinical practice. METHODS: This cohort study (NISSC1-LTE) followed up patients with systemic sclerosis included in the prospective European Society for Blood and Marrow Transplantation NISSC1 study who had undergone their first autologous HSCT for severe progressive systemic sclerosis. Follow-up data were collected from 13 participating centres in France, Germany, Netherlands, Italy, Spain, Switzerland, and Brazil. Participating centres completed a yearly case report form for each patient alive after 2 years and up to 10 years after autologous HSCT. The primary endpoint was progression-free survival, defined as survival from baseline without evidence of systemic sclerosis progression. Late complications after autologous HSCT, including malignancies, secondary autoimmune diseases, infections, and major adverse cardiovascular events were also analysed. People with lived experience of systemic sclerosis were involved in the design and conduct of this study. The NISSC1 study is registered with ClinicalTrials.gov (NCT02516124) and is complete. FINDINGS: All 80 patients with systemic sclerosis who had an autologous HSCT between Dec 4, 2012, and Jan 19, 2016, were included in this long-term extension study. 12 patients were lost to follow-up, including five patients with a follow-up less than 5 years. Median age at autologous HSCT was 43 years (IQR 33-51), 57 (71%) of 80 patients were female, 23 (29%) were male, and median follow-up was 9·2 years (IQR 8·9-9·6) after autologous HSCT. Progression-free survival was 81% (95% CI 71-88) at 2 years, 72% (61-81) at 5 years, and 60% (47-71) at 10 years. 18 patients died during the study; causes of death were autologous HSCT-related in five (6%) of 80 patients, disease progression in nine (11%) patients, post-autologous HSCT malignancy in two (3%) patients, and late serious infection in two (3%) patients. 34 (43%) of 80 patients maintained remission without immunosuppressive treatment over 10 years. INTERPRETATION: This study provides long-term follow-up data after autologous HSCT in patients with systemic sclerosis allowing robust assessment of response rate, late complications, and sustained treatment benefit. The extended timeframe might serve as an important comparator for all upcoming, cellular treatment options. FUNDING: None.
引用
- Henes J, Oliveira MC, Labopin M, et al. Long-term evaluation of the effectiveness and safety of autologous haematopoietic stem-cell transplantation for systemic sclerosis (NISSC1-LTE): a cohort study. Lancet Rheumatol. 2026. PMID: 42956788. doi:10.1016/S2665-9913(26)00227-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。